Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Aug 15, 2018 6:49pm
206 Views
Post# 28468730

RE:RE:RE:RE:Luc hints that there is some reluctance in adopting Trogarzo

RE:RE:RE:RE:Luc hints that there is some reluctance in adopting Trogarzo
Always good to have your drug’s article published in the NEJM.

We routinely dissect these articles at grand rounds so the word will get out to all Physicians  about Ibalizumab.

It is free advertising and it is the best kind. Thera can also drop off the article(s) when they detail individual HIV docs.

Bfw



SPCEO1 wrote: I don't think there was any new ground broken in these articles. All of it has been talked about here some time ago. Having NEJM articles that are positive about your drug is a helpful thing, but I doubt it moves the sales meter significantly. For any who might have been questioning the data, it will help alleviate their concerns. But there likely are very few such doctors anyway. 

PoorOpinion wrote: Fantastic journal. Articles are behind a paywall here (https://www.nejm.org)

A review here. Not without issues. Seems the FDA are prepared to discuss the limitations of the trial.
https://www.medpagetoday.com/hivaids/hivaids/74585

 




Bullboard Posts